Tobira Therapeutics Raises $31M

San Diego and Princeton, New Jersey-based Tobira Therapeutics said last night that it has completed $31M in a Series A financing. The newly created firm is developing treatments for HIV/AIDs. The funding for the company came from Domain Associates and Frazier Healthcare Ventures, which co-led the round, along with Montreux Equity Partners and Canaan Partners. Tobira also said that it has named James Sapirstein as CEO and President. Tobira Therapeutics said that it will focus on clinical development of novel therapies for HIV/AIDS, based on technology and products licensed from Takeda Pharmaceutical Company Limited of Osaka, Japan. More information »